Abstract
The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.
Keywords: Alzheimer’s disease, clinical course, cohort study, dementia, europe, geographical variation, cognitive, functional, NPI, caregiver burden, hospital admission
Current Alzheimer Research
Title:Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Volume: 9 Issue: 8
Author(s): A. Salva, M.O. Rikkert, M. Tsolaki, P.-J. Ousset, F. Pasquier, J.M. Ribera-Casado, A.S. Rigaud, P. Robert, G. Rodriguez, E. Salmon, P. Martinez-Lage, P. Scheltens, A. Schneider, A. Sinclair, L. Spiru, J. Touchon, D. Zekry, B. Winblad, S. Andrieu, M. Boada, L. Hausner, L. Frolich, C. Cantet, V. Gardette, E. Reynish, S. Gillette, E. Aguera-Morales, S. Auriacombe, B. Vellas, R. Bullock, J. Byrne, V. Camus, A. Cherubini, M. Eriksdotter-Jonhagen, G.B. Frisoni, S. Hasselbalch and R.W. Jones
Affiliation:
Keywords: Alzheimer’s disease, clinical course, cohort study, dementia, europe, geographical variation, cognitive, functional, NPI, caregiver burden, hospital admission
Abstract: The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.
Export Options
About this article
Cite this article as:
Salva A., Rikkert M.O., Tsolaki M., Ousset P.-J., Pasquier F., Ribera-Casado J.M., Rigaud A.S., Robert P., Rodriguez G., Salmon E., Martinez-Lage P., Scheltens P., Schneider A., Sinclair A., Spiru L., Touchon J., Zekry D., Winblad B., Andrieu S., Boada M., Hausner L., Frolich L., Cantet C., Gardette V., Reynish E., Gillette S., Aguera-Morales E., Auriacombe S., Vellas B., Bullock R., Byrne J., Camus V., Cherubini A., Eriksdotter-Jonhagen M., Frisoni G.B., Hasselbalch S. and Jones R.W., Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251066
DOI https://dx.doi.org/10.2174/156720512803251066 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano Clinoptilolite: Highly Efficient Catalyst for the Synthesis of Chromene Derivatives Under Solvent-Free Conditions
Combinatorial Chemistry & High Throughput Screening Juvenile Neuronal Ceroid-Lipofuscinosis (Batten Disease): A Brief Review and Update
Current Molecular Medicine Neuropsychiatric Symptoms and Functional Status in Alzheimer’s Disease and Vascular Dementia Patients
Current Alzheimer Research Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review
Current Alzheimer Research Gene Expression Suggests Spontaneously Hypertensive Rats May Have Altered Metabolism and Reduced Hypoxic Tolerance
Current Neurovascular Research A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Structural Characterization of Amyloid β17-42 Dimer by Potential of Mean Force Analysis: Insights from Molecular Dynamics Simulations
Protein & Peptide Letters Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics Genomics and Pharmacogenomics of Brain Disorders
Current Pharmaceutical Biotechnology Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Modulatory Effects of pH, Cu+2 and Sheet Breakers on Aggregation of Amyloid Peptides
Protein & Peptide Letters Prion-like Mechanisms in Alzheimer's Disease
Current Alzheimer Research Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor
Cardiovascular & Hematological Agents in Medicinal Chemistry Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry